Skip to main content
Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma With Thomas Hutson, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma With Thomas Hutson, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Thomas Hutson, Director of the Urologic Oncology Cancer Research and Treatment Center at Baylor Sammons Cancer Center, discusses the resul...
Reducing Drug Waste Through Dose Rounding of Bevacizumab With Puneeth Indurlal, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Reducing Drug Waste Through Dose Rounding of Bevacizumab With Puneeth Indurlal, MD In this interview from the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, Dr. Puneeth Indurlal, Senior Director for Care Transformation at the US Oncology Network, discusses his team's abstract regarding dose rounding of bevacizumab, the potential for minimizing drug waste, and reducing the cost of care.  
Impacts of Social Determinants of Health on Triple-Negative Breast Cancer Treatment With Nicholas Robert, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Impact of Social Determinants of Health on TNBC Treatment With Nicholas Robert, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor speaks with Dr. Nicholas Robert, Chief Medical Officer for Ontada, about his team's abstract regarding the impacts of social determinants of health on genetic testing and treatment selection in triple-negative breast cancer (TNBC).  
Supporting Patients Through Employment Disruptions During Cancer With Michael Halpern, MD, PhD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor® · Supporting Patients Through Employment Disruptions During Cancer With Michael Halpern, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Michael Halpern, Medical Officer in the National Cancer Institute's Healthcare Delivery Research Program, discusses his team's study investigating the effects of employment disruptions on financial hardship experienced by patients with cancer. Dr. Halpern shares advice for how employers can provide support and accommodation in the workplace for their employees during cancer treatment, as well as advice for clinicians on how to partner with patients to address financial hardships.  
Exploring the ARTISTRY-7 Trial of Nemvaleukin Alfa in Ovarian Cancer With Noelle Cloven, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Exploring the ARTISTRY-7 Trial of Nemvaleukin Alfa in Ovarian Cancer With Noelle Cloven, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Noelle Cloven, a Gynecologic Oncologist at the Sarah Cannon Research Institute at Texas Oncology, sat down with Oncology Data Advisor to furthe...
Hematology/Oncology Trainee Experiences During the COVID-19 Pandemic and Beyond With Samuel Kareff, MD, MPH, and Ana Velazquez Mañana, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Hematology/Oncology Trainee Experiences During COVID-19: Samuel Kareff and Ana Velazquez Mañana This Oncology Data Advisor® Fellows Forum Interview features Dr. Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, in discussion with Dr. Ana Velazquez Mañana, an Assistant Professor of Medicine in the Division of Hematology-Oncology at the University of California, San Francisco (UCSF), regarding the unique challenges faced by hematology/oncology trainees during the COVID-19 pandemic. Dr. Velazquez Mañana outlines the impacts on clinical training, research, and career development, as well as the positive changes that have been incorporated into the landscape for hematology/oncology trainees.  
Improving Outcomes for IDH1/2-Mutant Glioma in the INDIGO Study With Timothy Cloughesy, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving Outcomes for IDH1/2-Mutant Glioma in the INDIGO Study With Timothy Cloughesy, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Timothy Cloughesy, Director of the Neuro-Oncology Program at the University of California Los Angeles (UCLA), sat down to further discuss his presen...
Metastatic Castration-Sensitive Prostate Cancer: Real-World Characteristics and Treatment by Disease Volume With Stephen Freedland, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · mCSPC: Real World Characteristics and Treatment by Disease Volume With Stephen Freedland, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, sat down with Oncology Data Advisor to discuss his abstract regarding ...
Leveraging Community-Academic Partnerships to Improve Care for Latinx AYA Cancer Survivors With Stephanie Smith, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Leveraging Community-Academic Partnerships for Latinx AYA Cancer Survivors With Stephanie Smith, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephanie Smith, Pediatric Oncologist at Stanford Medicine, sat down with Oncology Data Advisor to discuss her research on leveraging community-academic partnerships to improve access to survivorship care for Latinx adolescent/young adult (AYA) cancer survivors. Dr. Smith explains the barriers faced by this population and the unique role that community cancer centers play in providing equitable care as patients transition into adult survivorship.  
Metastatic Castration-Sensitive Prostate Cancer: Real-World Characteristics and Treatment by Disease Volume With Stephen Freedland, MD
Nate Bargo
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, sat down with Oncology Data Advisor to discuss his abstract regarding real-world characteristics and treatment by disease volume among patients with metastatic castration-sensitive prostate cancer. Dr. Freedland shares more regarding the complexities of treatment decisions in prostate cancer, barriers to care, and the research that he and his team are conducting to optimize treatment utilization based on disease characteristics.  
Coping With the Uncertainty of Indolent Non-Hodgkin Lymphoma With Richard Newcomb, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Coping With the Uncertainty of Indolent Non-Hodgkin Lymphoma With Richard Newcomb, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Richard Newcomb, Hematology/Oncology Fellow at Dana-Farber/Mass General Cancer Center, sat down with Oncology Data Advisor to elaborate on his study regarding uncertainty and coping experienced by patients with newly diagnosed indolent non-Hodgkin lymphoma (NHL), as well as strategies for supporting patients facing distress around their diagnosis.  
Payment Reform Through the Enhancing Oncology Model With Lalan Wilfong, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Payment Reform Through the Enhancing Oncology Model With Lalan Wilfong, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down for a conversation with Dr. Lalan Wilfong, the Senior Vice President of Payer and Care Transformation for the US Oncology ...
Finding Real-World Response End Points in NSCLC Data Sets With Janet Espirito, PharmD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Finding Real-World Response End Points in NSCLC Data Sets With Janet Espirito, PharmD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Janet Espirito, PharmD, a Senior Medical Director at Ontada, sat down with Oncology Data Advisor to discuss her presentation on identifying real-world end points for assessing response in patients receiving novel therapies for metastatic non–small cell lung cancer (NSCLC) outside of clinical trials.  
Coaching Cancer Survivors Through Digital Health With Robin Lally, PhD, and Marilyn Hammer, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Coaching Cancer Survivors Through Digital Health: Robin Lally, PhD, and Marilyn Hammer, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down for a conversation with Robin Lally, PhD, and Marilyn Hammer, PhD, co–Principal Investigators of the COAC...
Coaching Cancer Survivors Through Digital Health With Robin Lally, PhD, and Marilyn Hammer, PhD
Keira Smith
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down for a conversation with Robin Lally, PhD, and Marilyn Hammer, PhD, co–Principal Investigators of the COACH (Comprehensive Outcomes for After-Cancer Health) study. Dr. Lally and Dr. Hammer share the background of this study and how it is seeking to improve the cancer survivorship experience through digital health interventions and patient-reported outcomes.  
Understanding Sexual Orientation and Gender Identity Data Collection in Oncology With Mandi Pratt-Chapman, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Understanding Sexual Orientation and Gender Identity Data Collection: Mandi Pratt-Chapman, PhD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Mandi Pratt-Chapman, Associate Center Director for Community Outreach, Engagement, and Equity at George Washington University Cancer Center, sat down with Oncology Data Advisor to discuss her abstract on difference-making conditions associated with sexual orientation and gender identity (SOGI) data collection among ASCO members' institutions. Dr. Pratt-Chapman gives additional insight into the importance of SOGI data collection for providing patient-centered care and shares advice for instituting data collection processes in order to help guide clinical decision making for LGBTQIA+ patients.  
Molecular Analyses of Sacituzumab Govitecan in Urothelial Carcinoma With Manoj Bupathi, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Molecular Analyses of Sacituzumab Govitecan in Urothelial Carcinoma With Manoj Bupathi, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Manojkumar Bupathi, MD, MS, a Genitourinary (GU) Medical Oncologist at Sarah Cannon Research Institute and Rocky M...
Reducing Cost of Cancer Care Through Novel Therapy Adjustment With Erica Feinberg, PharmD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Reducing Cost of Cancer Care Through Novel Therapy Adjustment With Erica Feinberg, PharmD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Erica Feinberg, PharmD, BCPS, a Senior Clinical Data Analyst at The US Oncology Network, to discuss her post...
Expert Perspectives in the Management of Triple-Negative Breast Cancer: a Webinar Preview With Sara Tolaney, MD, MPH
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Expert Perspectives in the Management of Triple-Negative Breast Cancer:Webinar Preview, Sara Tolaney i3 Health recently hostedPathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC): Case Explorations and Answers to FAQs, an accredited CME/NCPD webinar now available on...
Navigating the Residency and Fellowship Experience by Creating Opportunities in Oncology With Waqas Haque, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Navigating the Fellowship Experience by Creating Opportunities in Oncology With Waqas Haque In this Oncology Data Advisor® Fellows Forum interview, member Waqas Haque, MD, an Internal Medicine Resident at New York University, shares his medical training journey, the research he has conducted as Clinical Investiga...